相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2014)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia
Guido Finazzi et al.
BLOOD (2014)
Presence of calreticulin mutations in JAK2-negative polycythemia vera
Julien Broseus et al.
BLOOD (2014)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Calreticulin mutations and long-term survival in essential thrombocythemia
A. Tefferi et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
A. Tefferi et al.
LEUKEMIA (2014)
Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
Bruno Cassinat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
Gilles Bonicelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Emil T. Kuriakose et al.
HAEMATOLOGICA (2013)
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice
A. Tefferi et al.
LEUKEMIA (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Silvia Pascale et al.
BLOOD (2012)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui et al.
BLOOD (2012)
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
Francesco Passamonti et al.
BLOOD (2012)
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
Mandy Brecqueville et al.
GENES CHROMOSOMES & CANCER (2012)
Germline JAK2 Mutation in a Family with Hereditary Thrombocytosis
Adam J. Mead et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
A. Pardanani et al.
LEUKEMIA (2011)
DNMT3A mutations in myeloproliferative neoplasms
F. Stegelmann et al.
LEUKEMIA (2011)
Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
Ayaew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
Elena Crisa et al.
ANNALS OF HEMATOLOGY (2010)
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
Ersi Voskaridou et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
Elaine M. Boyd et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies
F. Passamonti et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Co-present rheumatoid arthritis and gout successfully treated with abatacept
Mariusz J. Puszczewicz et al.
CLINICAL RHEUMATOLOGY (2009)
Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
Naseema Gangat et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia
Kun Liu et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Two rare MPL gene mutations in patients with essential thrombocythemia
Haruhiko Ohashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Bone Marrow Fibrosis and Diagnosis of Essential Thrombocythemia
Juergen Thiele et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Mutant molecules of interest in myeloproliferative neoplasms: Introduction
Ayalew Tefferi
ACTA HAEMATOLOGICA (2008)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
Philip A. Beer et al.
BLOOD (2008)
Abatacept:: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
Andrew J. K. Oestoer
CLINICAL RHEUMATOLOGY (2008)
Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the abatacept in inadequate responders to methotrexate (AIM) trial
Tracy Li et al.
CLINICAL THERAPEUTICS (2008)
The Role of Clopidogrel and Acetylsalicylic Acid in the Prevention of Early-Phase Graft Occlusion Due to Reactive Thrombocytosis after Coronary Artery Bypass Operation
Ilyas Kayacioglu et al.
HEART SURGERY FORUM (2008)
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
G. Finazzi et al.
LEUKEMIA (2008)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T. L. Lasho et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Annette H. Schmitt-Graeff et al.
HAEMATOLOGICA (2007)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
Francesco Passamonti et al.
BLOOD (2007)
Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
Akyalew Tefferi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
Paola Guglielmelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
L. Shvidel et al.
LEUKEMIA (2007)
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: A distinct aspirin-responsive and coumadin-resistant arterial thrombophilia
Jan Jacques Michiels et al.
PLATELETS (2006)
The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera
Jan J. Michiels et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
C James et al.
LEUKEMIA (2006)
Essential thrombocythemia/polycythemia vera and pregnancy: The need for an observational study in Europe
Martin Griesshammer et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
JAK2V617F mutation in essential thrombocythaemia:: clinical associations and long-term prognostic relevance
AP Wolanskyj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
MA Elliott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman
F Passamonti et al.
ANNALS OF HEMATOLOGY (2004)
Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia
JJ Michiels et al.
ANNALS OF HEMATOLOGY (2004)
Pregnancy in essential thrombocythaemia: experience with 40 pregnancies
R Niittyvuopio et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycytheinia (ECLAP)
G Finazzi
PATHOLOGIE BIOLOGIE (2004)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
F Ding et al.
BLOOD (2004)
Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman:: occurrence of leukaemic evolution
V De Sanctis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Thrombocythaemia and pregnancy
MA Elliott et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2003)
Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera
A Baldo et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus
A Tefferi et al.
BLOOD (2002)
Pruritus in polycythaemia vera: prevalence, laboratory correlates and management
F Diehn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
A single institutional experience with 43 pregnancies in essential thrombocythemia
CA Wright et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
分享论文
